Top

Published in:

Open Access 01-10-2009 | Original Article

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

Authors: P. J. Meunier, C. Roux, S. Ortolani, M. Diaz-Curiel, J. Compston, P. Marquis, C. Cormier, G. Isaia, J. Badurski, J. D. Wark, J. Collette, J. Y. Reginster

Published in: Osteoporosis International | Issue 10/2009

Abstract

Summary

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis.

Introduction

Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate.

Methods

A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated.

Results

Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST®, was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups.

Conclusion

In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women.

European Prospective Osteoporosis Study (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724CrossRef

Cummings SR, Melton LJ, III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRef

Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRef

Center JR, Nguyen TV, Schneider D et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882PubMedCrossRef

Puffer S, Torgerson DJ, Sykes D et al (2004) Health care costs of women with symptomatic vertebral fractures. Bone 35:383–386PubMedCrossRef

Schwenkglenks M, Lippuner K, Hauselmann HJ et al (2005) A model of osteoporosis impact in Switzerland 2000–2020. Osteoporos Int 16:659–671PubMedCrossRef

Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMed

Oleksik AM, Ewing S, Shen W et al (2005) Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 16:861–870PubMedCrossRef

Brenneman SK, Barrett-Connor E, Sajjan S et al (2006) Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 212:809–816CrossRef

10.

Fechtenbaum J, Cropet C, Kolta S et al (2005) The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 16:2175–2179PubMedCrossRef

11.

Marie PJ, Ammann P, Boivin G et al (2001) Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121–129PubMedCrossRef

12.

Brennan TC, Rybchyn MS, Halbout P et al (2007) Strontium ranelate effects in human osteoblasts support its uncoupling effect on bone formation and bone resorptions. Bone Miner Res 22(Suppl.1):S139

13.

Meunier PJ, Slosman DO, Delmas PD et al (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066PubMedCrossRef

14.

Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 350:459–468PubMedCrossRef

15.

Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822PubMedCrossRef

16.

Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis and Rheumatism 58(6):1687–1695PubMedCrossRef

17.

Slosman DO, Rizzoli R, Pichard C et al (1994) Longitudinal measurement of regional and whole-body bone mass in young healthy adults. Osteoporos Int 4:185–190PubMedCrossRef

18.

Meunier PJ, Reginster JY (2003) Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 14(Suppl 3):S66–S76PubMed

19.

Genant HK, Wu CY, van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRef

20.

Melton LJ III, Thamer M, Ray NF et al (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23PubMedCrossRef

21.

Slosman DO, Provvedini DM, Meunier PJ et al (1999) The use of different dual x-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 2:37–44CrossRef

22.

Nielsen SP, Slosman D, Sorensen OH et al (1999) Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 2:371–379PubMedCrossRef

23.

Ware JE, Kosinski MK, Keller SD (1994) SF-36 physical and mental health summary scales: a users manual. The Health Institute, New England Medical Center, Boston, MA, USA

24.

Marquis P, Cialdella P, De la Loge C (2001) Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res 10:555–566PubMedCrossRef

25.

De la Loge C, Sullivan K, Pinkney R et al (2005) Cross-cultural validation and analysis of responsiveness of the QUALIOST: QUAlity of Life questionnaire In OSTeoporosis. Health Qual Life Outcomes 3:69PubMedCrossRef

26.

Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRef

27.

Delmas PD, Ensrud KE, Adachi JD et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomised clinical trial. J Clin Endocrinol Metab 87:3609–3617PubMedCrossRef

28.

Sorensen OH, Crawford GM, Mulder H et al (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120–126PubMedCrossRef

29.

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352PubMedCrossRef

30.

Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91PubMedCrossRef

31.

Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841–1850PubMedCrossRef

32.

Stepan JJ, Alenfeld F, Boivin G et al (2003) Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37:225–238PubMed

33.

Hansdottir H, Franzson L, Prestwood K, Sigurdsson G (2004) The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779–783PubMedCrossRef

34.

Marie PJ (2005) Strontium ranelate: a novel mode of action of optimizing bone formation and resorption. Osteoporos Int 16(Suppl 1):S7–S10PubMedCrossRef

35.

Baron R, Tsouderos Y (2002) In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450:11–17PubMedCrossRef

36.

Chattopadhyay N, Quinn SJ, Kifor O (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 74:438–447PubMedCrossRef

37.

Brown EM, Pollak M, Hebert SC (1998) The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 49:15–29PubMedCrossRef

38.

Boivin G, Farlay D, Simi C, Meunier PJ (2006) Bone strontium distribution and degree of mineralisation of bone in postmenopausal women treated with strontium ranelate for 2 or 3 years. Osteoporos Int 17:S86

39.

Boivin G, Meunier PJ (2006) Bone strontium content reaches a plateau after 3 years of treatment with strontium ranelate 2 g per day. Arthritis Rheum 9(Suppl):S59040

40.

Bruyere O, Roux C, Detilleux J et al (2007) Relationship between bone mineral density changes ans fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92(8):3076–3081PubMedCrossRef

41.

Bruyere O, Roux C, Badurski J et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranealte. Cur Med Res Op 23(12):3041–45CrossRef

42.

Marquis P, Roux C, de la Loge C et al (2007) Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 19:503–510PubMedCrossRef

43.

Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 55:505–509PubMed

44.

Silverman SL, Minshall ME, Shen W et al (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619PubMedCrossRef

45.

Nevitt MC, Chen P, Dore RK et al (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17:273–280PubMedCrossRef

Title: Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
Authors: P. J. Meunier
C. Roux
S. Ortolani
M. Diaz-Curiel
J. Compston
P. Marquis
C. Cormier
G. Isaia
J. Badurski
J. D. Wark
J. Collette
J. Y. Reginster
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0825-6

2024 ASCO Annual Meeting

Springer Medicine

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2009

Determinants of 25-hydroxyvitamin D levels in African-American and Caucasian male veterans

Comparative gastrointestinal safety of weekly oral bisphosphonates

Effect of impact exercise on bone metabolism

Use of anti-depressants and the risk of fracture of the hip or femur

Osteoporosis in China

BMD, clinical risk factors and their combination for hip fracture prevention